Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



Theranexus announces appointment of Jérôme Martinez to its Board of Directors
13/12/2018
Download PDF File (370 Ko)

Theranexus September 30th cash position and business update
09/11/2018
Download PDF File (369 Ko)

Theranexus announces inclusion of last patient in phase II trial of drug candidate THN102 on narcolepsy patients

29/10/2018
Download PDF File (371 Ko)

Theranexus plans to extend its phase 2 pipeline with a third program

15/10/2018
Download PDF File (382 Ko)

Theranexus announces that Rodolphe Besserve will join its Board of Directors

11/10/2018
Download PDF File (368 Ko)

January 22nd 2019: Biomed conference, Paris